Despite the transformative clinical impact of programmed cell death ligand 1/programmed death 1 (PD-1/PD-L1) blockade in hepatocellular carcinoma (HCC), therapeutic efficacy remains limited by the tumor immunosuppressive microenvironment (TIME), with objective response rates persistently below 20 %. This evidence concerns the gene CD274 and neoplasm.